Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Beijing Biostar Pharms Co Ltd (2563.HK)
Beijing, CN
Beijing Biostar Pharmaceuticals Co. Ltd. primarily focuses on developing innovative therapies for tumors. The company is dedicated to creating novel anti-cancer drugs, each secured by independent intellectual property rights. A prominent product in its portfolio is the Utidelone injection, a next-generation microtubule inhibitor produced through a unique microbial fermentation process. This enterprise was co-founded by Li Tang and Rong Guo Qiu on July 11, 2002, and operates from its headquarters in Beijing, China.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +2.88% | -15.08% | -28.19% | -14.40% | +9.18% | -34.36% | -27.21% | -84.57% | -84.57% | -84.57% | -84.57% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-03 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Drug Manufacturers - General: +6.6%-52.4% Q4'25: -47.6% (vs Q4'24)
-
EPS growth Drug Manufacturers - General: +18.2%+9.3% Q4'25: -8.3% (vs Q4'24)
-
FCF margin FCF growth · Drug Manufacturers - General: +36.0%-548.7% Q4'25: -296.8% (vs Q4'24)
-
EBIT margin Drug Manufacturers - General: +19.4%-407.9% Q4'25: -421.6% (vs Q4'24)
-
ROIC Drug Manufacturers - General: +10.2%-64.4% Q4'25: -109.0% (vs Q4'24)
-
Share dilution Drug Manufacturers - General: +0.0%+0.1% Q4'25: +4.1% (vs Q4'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - General: -0.29×-0.02× Q4'25: -0.01× (vs Q4'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
77.92M
est: 86.00M (-9.4%)
|
37.12M
est: 206.00M (-82.0%)
|
501.00M
501.00M – 501.00M
+143.2% YoY
|
| EBITDA |
-173.74M
est: -86.00M (-102.0%)
|
-139.87M
est: -206.00M (+32.1%)
|
-501.00M
-501.00M – -501.00M
-143.2% YoY
|
| EBIT |
-184.38M
est: -86.00M (-114.4%)
|
-151.39M
est: -206.00M (+26.5%)
|
-501.00M
-501.00M – -501.00M
-143.2% YoY
|
| Net Income |
-155.89M
est: -135.09M (-15.4%)
|
-142.54M
est: -108.43M (-31.5%)
|
55.86M
55.86M – 55.86M
+151.5% YoY
|
| SGA |
44.50M
est: 183.84M (-75.8%)
|
42.54M
est: 440.37M (-90.3%)
|
1.07B
1.07B – 1.07B
+143.2% YoY
|
| EPS |
-0.43
est: -0.37 (-16.2%)
|
-0.39
est: -0.30 (-31.3%)
|
0.15
0.15 – 0.15
+151.5% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-10 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-09 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
| 2026-06-03 | C | 2/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 3/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Li Tang | Co-Founder, Chairperson, Chief Scientific Officer & Chief Marketing Officer | 3M | — |
| Rongguo Qiu | Co- Founder, Vice-Chairperson, Chief Executive Officer & GM | 3M | — |
| Jin Guan | Deputy GM & Executive Director | 1M | — |
| Cheng Zhang | Deputy GM, Vice President & Executive Director | 746.0K | male |
| Wei He | Head of administration | — | — |
| Aoshuang Huang | Human Resource Director | — | — |
| Xin Chen | Operation Director | — | — |
| Fei Peng | Financial Director | — | male |
| Kailin Liu | Investment Director & Joint Company Secretary | — | male |
| Mingwu Yang | Head of equipment power | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 2563.HK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
